

Live - Euronext Paris - 02/17 - 10:00 AM

CVX - FR0013333077 ✓ PEA ✓ PEA-PME

Carvolix

4,120 € **+1.23%**

[See the advice](#) ⓘ



[Price](#)

[News & Advice](#)

[Derivatives](#)

[History](#)

[Company](#)

ANALYST RECOMMENDATIONS

Invest Securities upgrades Carvolix: “Cardiovascular innovation meets robotics”

Shares in the medtech firm soared as much as 15% today. Their value has more than doubled since the start of the year.



(Affluent Medical)

By [The Investir Editorial Team](#)

Published on February 16, 2026 at 4:36 PM

The medtech company Carvolix, specializing in AI-powered interventional cardiology, was officially launched on January 30 following the merger of Affluent Medical, Caranx, and Artedrone. *“This move has created a comprehensive product portfolio for interventional cardiologists and neurologists. The targeted markets are promising, with a strong portfolio position that meets a significant medical need,”* notes Invest Securities, which recommends buying shares in the company with a target price of 4.2 euros.

Carvolix shares surged as much as 15% today on Euronext Paris. Their value has more than doubled since the start of the year. Affluent Medical had become a penny stock in 2023 and ended 2025 at 1.73 euros.

The financial analysis firm Invest Securities sums up the medtech's activity as follows: *“Cardiovascular care, powered by robotics.”* According to their assessment, Carvolix’s long-term funding requirements exceed 80 million euros, *“which could be met either by possible sales of Kalios and Artus, or through new fundraising efforts. In the latter case, expanding the product pipeline may help secure additional financing.”*

They believe that *“the integration of Caranx and Artedrone has generated an estimated value creation of over 113 million euros (or +1.5 euro per share).”*